Precigen Inc PGEN:NASDAQ

Last Price$1.41NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change+0.07(5.22%)
Bid (Size)$1.28 (1)
Ask (Size)$1.46 (50)
Day Low / High$1.31 - 1.41
Volume606.6 K

View Biotechnology IndustryPeer Comparison as of 07/01/2022


Precigen Inc ( NASDAQ )

Price: $1.41
Change: +0.07 (5.22%)
Volume: 606.6 K
4:00PM ET 7/01/2022

Alaunos Therapeutics Inc ( NASDAQ )

Price: $1.30
Change: +0.06 (4.84%)
Volume: 3.6 M
4:00PM ET 7/01/2022

bluebird bio Inc ( NASDAQ )

Price: $4.28
Change: +0.14 (3.38%)
Volume: 4.0 M
4:00PM ET 7/01/2022

Heron Therapeutics Inc ( NASDAQ )

Price: $2.72
Change: -0.07 (2.51%)
Volume: 3.0 M
4:00PM ET 7/01/2022

Scholar Rock Holding Corp ( NASDAQ )

Price: $5.33
Change: -0.16 (2.91%)
Volume: 869.1 K
4:00PM ET 7/01/2022

Read more news Recent News

-- Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $32M, vs. Street Est of $23.3M
4:39PM ET 5/09/2022 MT Newswires


Precigen's Acute Myeloid Leukemia Treatment Candidate Gets FDA Fast Track Designation
11:04AM ET 4/04/2022 MT Newswires

Precigen (PGEN) said Monday the US Food and Drug Administration granted fast track designation to its PRGN-3006 UltraCAR-T treatment for relapsed or...

-- Earnings Flash (PGEN) PRECIGEN Reports Q4 Revenue $24.2M, vs. Street Est of $22.2M
8:02AM ET 3/01/2022 MT Newswires


Insider Buy: Precigen
5:06PM ET 11/30/2021 MT Newswires

Harry Thomasian Jr., Chief Financial Officer, on November 26, 2021, executed a purchase for 26,500 shares in Precigen (PGEN) for $100,831. Following the...

Company Profile

Business DescriptionPrecigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
Address20358 Seneca Meadows Parkway
Germantown, Maryland 20876
Number of Employees882
Recent SEC Filing06/14/20228-K
President, Chief Executive Officer & DirectorHelen Sabzevari
Vice President, Head-Operations & PortfolioRutul R. Shah
Chief Financial OfficerHarry Thomasian
Chief Science OfficerThomas David Reed

Company Highlights

Price Open$1.35
Previous Close$1.34
52 Week Range$1.12 - 6.63
Market Capitalization$292.8 M
Shares Outstanding207.7 M
SectorHealth Technology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.47
Beta vs. S&P 500N/A
Revenue$160.6 M
Net Profit Margin-84.55%
Return on Equity-79.87%

Analyst Ratings as of 05/10/2022

Consensus RecommendationConsensus Icon
Powered by Factset